{"entity":{"id":"jyp0015","kind":"drug","name":"JYP0015","aka":[],"tldr":"JYP0015 is an experimental small-molecule drug from Guangzhou JOYO Pharma in phase 2 trials for pancreatic ductal adenocarcinoma, non-small-cell lung cancer and colorectal cancer, aimed at KRAS.","summary":"JYP0015 is a small-molecule drug developed by Guangzhou JOYO Pharma. Its target is KRAS (the sponsor names KRAS, NRAS, HRAS (pan-RAS)). The sponsor states: An orally bioavailable pan-RAS inhibitor designed to selectively target the active (ON) form of wild-type and mutant RAS across KRAS, NRAS and HRAS isoforms, including mutations at codons 12, 13, 61, 117 and 146. ClinicalTrials.gov describes the intervention as: JYP0015 is an orally bioavailable pan-RAS inhibitor designed to target the active (ON) form of wild-type and mutant RAS across KRAS, NRAS, and HRAS isoforms. The drug will be administered orally, with dosing determined by the study protocol. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in pancreatic ductal adenocarcinoma, non-small-cell lung cancer and colorectal cancer. The largest, NCT06895031, plans to enrol 210 participants with primary completion was scheduled for 2026-03-30 on the registry. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of JYP0015","url":"https://clinicaltrials.gov/search?intr=JYP0015"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["pancreatic","nsclc","colorectal"],"sections":[],"technologies":[],"targets":["kras","nras"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct06895031"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"small molecule (structure undisclosed or not yet in PubChem)","mechanism":"An orally bioavailable pan-RAS inhibitor designed to selectively target the active (ON) form of wild-type and mutant RAS across KRAS, NRAS and HRAS isoforms, including mutations at codons 12, 13, 61, 117 and 146.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/jyp0015/","neighbours":{"cancer":[{"id":"colorectal","kind":"cancer","name":"Colorectal cancer","route":"/cancers/colorectal/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"target":[{"id":"hras","kind":"target","name":"HRAS","route":"/targets/hras/"},{"id":"kras","kind":"target","name":"KRAS","route":"/targets/kras/"},{"id":"nras","kind":"target","name":"NRAS","route":"/targets/nras/"}],"trial":[{"id":"nct06895031","kind":"trial","name":"Study of JYP0015 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS","route":"/trials/nct06895031/"}]}}